Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempegaldesleukin + Nivolumab vs Nivolumab in Adjuvant Melanoma (PIVOT-12)
NCT04410445Phase 3Terminated
- Sponsor
- Nektar Therapeutics
- Start
- Jul 2020
- Primary completion
- Sep 2022
- Modality
- Cytokines & Interferons
- Countries
- 17
01
Overview
A Phase 3 trial of bempegaldesleukin in melanoma, sponsored by Nektar Therapeutics. Started Jul 2020; status: terminated.
02
Drugs
bempegaldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04410445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04410445.